Pharming Story

<div class='circular--portrait' style='background:#689CFD;color: #ffffff;font-size:4em;'>PG</div>
PHGUF -- USA Stock  

USD 1.31  0.01  0.77%

As many of us are excited about healthcare space, it is fair to digest Pharming Grp NV within current market trends. As we have suggested previously, Pharming Grp is beginning its dip as shareholders shift to be more bearish due to the increased sector volatility. The returns on investing in Pharming Grp and the market returns of the last few months appear uncorrelated. Unsteady basic indicators of the firm may also indicate signs of longer-term losses for Pharming shareholders. Pharming Grp NV is scheduled to announce its earnings today.
Published few days ago
View all stories for Pharming Grp | View All Stories
Our latest technical analysis of Pharming Grp NV (OTC:PHGUF)
Pharming Grp's average rating is Strong Buy from 2 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Pharming Grp market sentiment investors' perception of the future value of Pharming. Let us look at a few aspects of Pharming technical analysis.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Pharming Grp NV. In general, we focus on analyzing Pharming Grp stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Pharming Grp's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Pharming Grp's intrinsic value. In addition to deriving basic predictive indicators for Pharming Grp, we also check how macroeconomic factors affect Pharming Grp price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Pharming Grp's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Pharming Grp in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Pharming Grp. Your research has to be compared to or analyzed against Pharming Grp's peers to derive any actionable benefits. When done correctly, Pharming Grp's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Pharming Grp NV.

Watch out for price decline

Please consider monitoring Pharming Grp on a daily basis if you are holding a position in it. Pharming Grp is trading at a penny-stock level, and the possibility of delisting is much higher compared to other equities. However, just because the otc stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Pharming Grp stock to be traded above the $1 level to remain listed. If Pharming Grp stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

How does Pharming Stands against Peers?

Analyzing Pharming Grp competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Pharming Grp across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out Pharming Grp Competition Details

How Pharming utilizes its cash?

To perform a cash flow analysis of Pharming Grp, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Pharming Grp is receiving and how much cash it distributes out in a given period. The Pharming Grp cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Detailed Outlook On Pharming Grp

This firm has a beta of -0.0718. Let's try to break down what Pharming's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Pharming Grp will likely underperform. The beta indicator helps investors understand whether Pharming Grp moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Pharming deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. The company reported the revenue of 218.53 M. Net Income was 38.43 M with profit before overhead, payroll, taxes, and interest of 165.09 M.

Price may slide back for Pharming in May

Variance is down to 9.85. It may indicate a possible volatility dip. Pharming Grp NV exhibits very low volatility with skewness of 0.95 and kurtosis of 2.44. However, we advise investors to further study Pharming Grp NV technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Pharming Grp's otc stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Pharming Grp's otc stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

The Current Takeaway on Pharming Grp Investment

Although few other entities in the biotechnology industry are either recovering or due for a correction, Pharming Grp may not be performing as strong as the other in terms of long-term growth potentials. To conclude, as of the 6th of April 2021, we believe that Pharming Grp is currently overvalued with low odds of financial distress in the next two years. Our latest 30 days recommendation on the firm is Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Pharming Grp NV. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com